Novanta (NOVT) Q4 2025: Bookings Surge 25% as Backlog and New Product Revenue Hit Record Highs
Novanta delivered a pivotal Q4, posting record bookings growth and broad-based momentum across all business units, despite near-term margin trade-offs from manufacturing transitions. The company’s robust backlog and new product wins set a durable base for mid-single-digit organic growth in 2026, while a strengthened balance sheet and $1.5B in acquisition capacity position Novanta for strategic expansion. Management’s focus on medical technology, consumables, and embedded software, combined with operational discipline, signals a shift toward higher resilience and long-term value creation.
Summary
- Backlog Power Shift: All four business units delivered double-digit bookings growth and positive book-to-bill, strengthening demand visibility.
- Margin Sacrifice for Delivery: Management prioritized customer shipments over cost, impacting near-term margins but preserving commercial momentum.
- Acquisition Readiness: $1.5B in capacity and a robust pipeline set the stage for larger, strategic M&A in 2026.
Performance Analysis
Novanta capped 2025 with record revenue and a 25% year-over-year bookings surge in Q4, reflecting broad-based demand across all major segments. The company’s book-to-bill ratio of 1.11% and double-digit bookings growth in every business unit underscore a significant inflection in backlog strength, not seen since 2022. New product revenue exceeded 80% growth in the quarter, raising the vitality index, a measure of sales from products launched in the past three years, to 24%—a clear testament to the company’s innovation pipeline and commercial execution.
While adjusted EBITDA and EPS delivered double-digit gains, gross margin and cash flow landed below prior guidance as Novanta deliberately prioritized customer deliveries over the pace of regional manufacturing transfers. This tactical decision resulted in higher dual running costs and elevated inventory, but management emphasized these were temporary, with corrective actions already underway. The company exited the year with a positive net cash position, having used proceeds from a $600M equity raise to pay down debt, and repurchased $40M in shares over the year.
- Bookings Momentum Broadens: Book-to-bill exceeded 1.0 across all business units, with medical and industrial segments each contributing roughly half of total sales.
- Innovation Drives Mix Shift: New product sales grew over 60% for the year, and design wins rose 20%, supporting future revenue streams.
- Temporary Margin Compression: Gross margin fell 150 basis points YoY due to dual manufacturing costs, but is expected to rebound as site moves complete.
Segment performance was mixed but trending positively: Medical Solutions grew 16% YoY in Q4, Automation Enabling Technology rose 2%, and Precision Manufacturing saw sequential revenue growth despite a modest YoY decline. Robotics and Automation posted 6% revenue growth, with strong tailwinds from AI-driven applications and semiconductor recovery.
Executive Commentary
"We said we would return to organic growth and double-digit profit growth in the fourth quarter, and we delivered. Booking surged 25% year-over-year and 12% sequentially with a book-to-bill of 1.11%. Every single business delivered double digit bookings growth and a positive book to bill in the same quarter. That's the first time that's happened since 2022."
Matthias Glostra, Chair and Chief Executive Officer
"Gross margins came in below our November guidance, a direct consequence of the decision Matthias described. Prioritizing customer deliveries over transfer timing created higher dual running costs in the quarter with more than 100 basis point impact to gross margin and a 400 basis point increase to networking capital as a percent of sales. In January, we adjusted the cost structure without disrupting deliveries or revenue momentum."
Robert Buckley, Chief Financial Officer
Strategic Positioning
1. Medical Technology Expansion
Medical sales now represent 53% of revenue, a dramatic shift from a decade ago, reflecting a deliberate focus on high-growth, less cyclical end markets. Novanta’s advanced surgery franchise—anchored by next-generation insufflators and consumables—continues to drive double-digit growth, with management targeting $400M in segment revenue by 2030. The company’s deep OEM relationships and regulatory expertise form a durable moat, as medical customers increasingly seek full-solution partners.
2. Embedded Software and Intelligent Subsystems
Embedded software, defined as proprietary code integrated with hardware to deliver unique subsystem functionality, is now central to 30% of Novanta’s business and the majority of new product launches. This vertical integration enables differentiation in beam steering, robotics, and surgical platforms, providing both pricing power and customer stickiness.
3. Acquisition Pipeline and Capital Allocation
With $1.5B in acquisition capacity following the equity raise, Novanta is positioned to pursue larger, high-return targets in medical consumables, bioprocessing, and embedded software. The company maintains strict return hurdles—requiring bolt-ons to exceed cost of capital by year two, and larger deals by year five—while seeking high-cash conversion, asset-light businesses that compound free cash flow.
4. Manufacturing Regionalization and Supply Chain Resilience
Regional manufacturing transfers, moving production closer to customer end markets, are designed to reduce geopolitical risk, improve on-time delivery, and lower long-term costs. While these moves temporarily pressured margins and working capital, management expects completion by Q2 2026, unlocking margin expansion and improved cash flow conversion.
5. AI and Robotics Tailwinds
AI-driven automation and robotics, especially in warehouse, surgical, and semiconductor applications, are creating durable multi-year tailwinds. Novanta’s unique position as the sole supplier for GPU board drilling spindles and its leadership in force-torque sensors for humanoid and warehouse robots underpin high single-digit growth expectations in these segments for 2026.
Key Considerations
Novanta’s Q4 marks an inflection point, with broad-based demand, innovation-led growth, and a clear capital allocation roadmap. The company is actively balancing short-term margin impacts with long-term strategic positioning.
Key Considerations:
- Backlog and Bookings Visibility: Sustained positive book-to-bill and record backlog across all units provide strong revenue visibility into 2026.
- New Product Vitality: Over 60% growth in new product sales and a rising vitality index signal continued innovation-led expansion.
- Manufacturing Transition Execution: Timely completion of regional site moves is critical for margin recovery and cash flow rebound.
- Acquisition Deployment: Effective use of $1.5B in capacity could accelerate growth and diversify end markets, but timing and valuation discipline remain key.
- AI and Robotics Leverage: Leadership in precision robotics, beam steering, and GPU board drilling positions Novanta to capture secular AI-driven demand.
Risks
Execution risk remains elevated around the completion of manufacturing site transfers, with any delays potentially impacting margin and cash flow recovery. Macroeconomic uncertainty, particularly in capital equipment and semiconductor cycles, could affect backlog conversion. The ability to deploy acquisition capital at attractive returns is not guaranteed, and integration risk rises with larger deals. Regulatory and data privacy challenges also loom as Novanta expands its embedded software and medical portfolio.
Forward Outlook
For Q1 2026, Novanta guided to:
- Organic revenue growth of 1% to 3%, with reported growth of 7% to 9%.
- Adjusted EBITDA of $56M to $58M, up 12% to 17% YoY.
For full-year 2026, management raised guidance:
- Organic revenue growth of 4% to 6%.
- Adjusted EBITDA of $245M to $250M, with margin expansion to 24%.
- EPS growth up to 11% despite dilution from the equity raise and all-employee equity grant.
- Operating cash flow rebound to $145M–$185M, more than double 2025.
Management highlighted several factors that underpin confidence:
- Record backlog and bookings strength, providing high revenue visibility.
- Completion of regional manufacturing moves unlocking margin and cash flow upside.
- Active pursuit of strategic acquisitions to accelerate growth and diversify exposure.
Takeaways
Novanta’s Q4 performance validates its innovation and commercial strategies, with broad-based bookings momentum and a robust pipeline for 2026 and beyond.
- Bookings and Backlog Surge: All business units posted double-digit bookings growth, providing strong visibility and supporting mid-single-digit organic growth guidance.
- Short-Term Margin Trade-Offs: Temporary margin compression from manufacturing transitions was a deliberate choice to protect customer relationships and delivery reliability, with normalization expected by Q2 2026.
- Strategic M&A Leverage: The company’s $1.5B acquisition firepower, coupled with strict return criteria, sets up for potentially transformative deals in medical and embedded software markets.
Conclusion
Novanta enters 2026 with record backlog, accelerating new product traction, and a clear path to margin recovery and cash flow rebound. The company’s disciplined capital allocation and operational execution underpin its strategy to deliver resilient, innovation-driven growth in high-value medical and industrial markets.
Industry Read-Through
Novanta’s results signal a broad-based recovery in medical technology, automation, and precision manufacturing end markets, with AI and robotics adoption driving multi-year demand. The company’s experience with regional manufacturing transfers foreshadows similar moves by other global suppliers seeking resilience amid geopolitical risk. The surge in new product revenue and design wins highlights the importance of innovation and embedded software in sustaining competitive advantage. Other industry participants should watch for continued consolidation, as well-capitalized players like Novanta leverage acquisition pipelines to accelerate growth and expand solution breadth, particularly in medical consumables and intelligent subsystems.